Cargando…

Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report

BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that excludes them from potentially curative surgical treatment. Lenvatinib is associated with a high objective response rate (ORR) (40.6%) in advanced HCC, indicating the potential for tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhaobo, Fu, Zhi, Li, Guangming, Lin, Dongdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568629/ https://www.ncbi.nlm.nih.gov/pubmed/33116607 http://dx.doi.org/10.2147/OTT.S261521

Ejemplares similares

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Downstaging and Pathological Complete Response of Locally Recurrent Sarcomatoid Renal Cell Carcinoma under Pembrolizumab and Lenvatinib: A Case Report and Review of Literature
por: Ell, Jascha, et al.
Publicado: (2023)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation
por: Biolato, Marco, et al.
Publicado: (2021)

Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy
por: Frankul, Leana, et al.
Publicado: (2021)

Liver transplantation in hepatocellular carcinoma – should we perform downstaging?
por: Filipec Kanižaj, Tajana, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Bang, Kyunghye, et al.
Publicado: (2022)

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
por: Gao, Qimeng, et al.
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging
por: Affonso, Breno Boueri, et al.
Publicado: (2019)

Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features
por: Wang, Si-Yuan, et al.
Publicado: (2023)

Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
por: Yokoo, Hideki, et al.
Publicado: (2020)

Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation
por: Kim, Deok Gie, et al.
Publicado: (2019)

Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma
por: Villalobos, Alexander, et al.
Publicado: (2021)

Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation—Adjusting the Odds?
por: Seehofer, Daniel, et al.
Publicado: (2022)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
por: Rehman, Obaid, et al.
Publicado: (2021)

Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma
por: Goyal, Manjeet Kumar, et al.
Publicado: (2023)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
por: Tao, Meng, et al.
Publicado: (2023)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy
por: Xu, Qinmei, et al.
Publicado: (2021)

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
por: Suzuki, Naomi, et al.
Publicado: (2020)

Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma
por: Uchida‐Kobayashi, Sawako, et al.
Publicado: (2022)

Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Du, Sihao, et al.
Publicado: (2023)

Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report
por: Kohya, Risako, et al.
Publicado: (2022)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Zhu, Jie, et al.
Publicado: (2021)

Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma
por: Legros, Laurence, et al.
Publicado: (2023)

Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report
por: Chen, Zhihong, et al.
Publicado: (2023)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis
por: Chen, Xinyu, et al.
Publicado: (2021)

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
por: Ohya, Yuki, et al.
Publicado: (2020)

T‐stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics
por: Hayes, Ian P., et al.
Publicado: (2022)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Downstaging of Hepatocellular Carcinoma Prior to Liver Transplant: Is There a Role for Adjuvant Sorafenib in Locoregional Therapy?
por: Vagefi, Parsia A., et al.
Publicado: (2010)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
por: Piñero, Federico, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ok40dapcraaekti52kfg8125i1